First-of-its-Kind cell therapy trial targets Hard-to-Treat scleroderma
NCT ID NCT07355972
Summary
This is an early, exploratory study to test the safety and initial effects of a new cell therapy called CT1195E in people with severe, worsening systemic sclerosis (scleroderma). The therapy involves collecting and genetically modifying a patient's own immune cells (CAR-T cells) to target the disease. The main goals are to find a safe dose and see how the body responds to the treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SSC-SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Wuhan Union Hospita
RECRUITINGWuhan, Hubei, 430000, China
Conditions
Explore the condition pages connected to this study.